Zobrazeno 31 - 40
of 495
pro vyhledávání: '"Keunchil Park"'
Autor:
Hyun Ae Jung, Jung Yong Hong, Moon Ki Choi, Won Jin Chang, Sung-min Kim, Moon Jin Kim, Keunchil Park, Hye Sook Kim, Jong-Mu Sun, Myung-Ju Ahn
Publikováno v:
The Korean Journal of Internal Medicine
The Korean Journal of Internal Medicine, Vol 34, Iss 5, Pp 1107-1115 (2019)
The Korean Journal of Internal Medicine, Vol 34, Iss 5, Pp 1107-1115 (2019)
Background/Aims We investigated the efficacy and toxicity of a weekly schedule of docetaxel and cisplatin as a first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Methods In this study, 18
Autor:
Sook J. Lee, Youjin Kim, Kyunga Kim, Se-Hoon Lee, Myung-Ju Ahn, Hong Sook Kim, Jin Seok Ahn, Sungjun Hong, Sang Won Seo, Jong-Mu Sun, Chu Hyun Kim, Keunchil Park, Ho Yun Lee, Hongui Cha
Publikováno v:
Journal of Thoracic Oncology. 14:1608-1618
Introduction Hyperprogressive disease (HPD), characterized by accelerated tumor progression, has been proposed as a new pattern of progression after immune checkpoint inhibitor (ICI) treatment. The aim of this study was to describe the characteristic
Autor:
Jun Zhao, B J Srinivasa, Hai-Yan Tu, Konstantin Laktionov, Filippo de Marinis, Tejaswini Jalikop, Jifeng Feng, Eng Huat Tan, Victor C. S. Lee, Cheng-Ta Yang, Dariusz M. Kowalski, Maya Gottfried, Yi-Long Wu, Artem Poltoratskiy, Dennis Chin-Lun Huang, Agnieszka Cseh, Keunchil Park, L. Clementi, Antonio Passaro
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
BackgroundAfatinib is approved for first-line treatment of patients with epidermal growth factor receptor mutation-positive (EGFRm+) non-small-cell lung cancer (NSCLC). Here, we report findings from a combined analysis of three phase IIIb studies of
Autor:
Keunchil Park, Hyun Ae Jung, Myung-Ju Ahn, Jin Seok Ahn, Dong Kyung Chang, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Oksoon Jeong
Publikováno v:
Transl Lung Cancer Res
BACKGROUND: The American Society for Clinical Oncology recently launched the minimal common oncology data elements project to facilitate cancer data interoperability. However, clinical data are often unrecorded in an organized way, and converting the
Autor:
Dariusz M. Kowalski, Keunchil Park, Vishal Boolell, Salma K. Jabbour, Steven M. Keller, Valeriy Breder, Amy Sanford, Nikolaj Frost, Baerin Houghton, A. Samkari, Martin Reck, Ki Hyeong Lee, Noemi Reguart, Hong Liu, Alex Martinez-Marti, Takefumi Komiya, Theodore Pollock, Jean Baptiste Paoli, Sufia Safina, Evgeny Levchenko
Publikováno v:
JAMA Oncol
IMPORTANCE: Administration of pembrolizumab plus concurrent chemoradiation therapy (cCRT) may provide treatment benefit to patients with locally advanced, stage III non–small cell lung cancer (NSCLC). OBJECTIVE: To evaluate treatment outcomes and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7609733e2099c09e1daaebba833b59f
https://europepmc.org/articles/PMC8446818/
https://europepmc.org/articles/PMC8446818/
Autor:
Wen Hong Lin, Carlos H. Barrios, Martin Reck, Ramaswamy Govindan, Neal Ready, Dimple Pandya, Hye Ryun Kim, Taofeek K. Owonikoko, Alejandro Navarro, Keunchil Park, Laurent Greillier, Ivor John Percent, Vanesa Gutierrez, Miten Patel, Jong Seok Lee, Parul Doshi, Michael Schenker, Solange Peters, Shaker R. Dakhil, Jerónimo Rodríguez-Cid, Daniel Morgensztern, Christine Baudelet, Sofia Baka, Jonathan F. Baden, Giovanni Selvaggi
Publikováno v:
Journal of clinical oncology, vol. 39, no. 12, pp. 1349-1359
Scientia
Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (12), pp.1349-1359. ⟨10.1200/JCO.20.02212⟩
Scientia
Journal of Clinical Oncology
Journal of Clinical Oncology, 2021, 39 (12), pp.1349-1359. ⟨10.1200/JCO.20.02212⟩
PURPOSE In extensive-disease small-cell lung cancer (ED-SCLC), response rates to first-line platinum-based chemotherapy are robust, but responses lack durability. CheckMate 451, a double-blind phase III trial, evaluated nivolumab plus ipilimumab and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::362dcb13447f71920cccc0d1cd6b0b79
https://serval.unil.ch/resource/serval:BIB_78F0D04B7BA3.P001/REF.pdf
https://serval.unil.ch/resource/serval:BIB_78F0D04B7BA3.P001/REF.pdf
Autor:
Myung-Ju Ahn, Yong Chan Ahn, Sung Hee Lim, Keunchil Park, Dongryul Oh, Man Ki Chung, Young-Ik Son, Chung-Hwan Baek, Jong-Mu Sun, Joohyun Hong, Han-Sin Jeong
Publikováno v:
The Korean Journal of Internal Medicine, Vol 36, Iss Suppl 1, Pp S217-S224 (2021)
The Korean Journal of Internal Medicine
The Korean Journal of Internal Medicine
Background/aims Clinical trials have not consistently supported the use of induction chemotherapy (IC) for locally advanced head and neck squamous cell cancer. Hypopharynx and base of tongue (BOT) cancer has shown relatively poor survival. We investi
Autor:
Jin Seok Ahn, Joon Young Choi, Keunchil Park, Jong-Mu Sun, Myung-Ju Ahn, Seung Hwan Moon, Byung-Tae Kim, Kyung-Han Lee
Publikováno v:
Scientific Reports, Vol 9, Iss 1, Pp 1-9 (2019)
We investigated the relationship between tumor 18F-fluorodeoxyglucose (FDG) uptake on positron emission tomography/computed tomography (PET/CT) scans and thymidylate synthase (TS) expression. In addition, we evaluated the value of FDG uptake in predi
Autor:
Myung-Ju Ahn, Tae Jung Kim, Tae Sung Kim, Keunchil Park, Bo Da Nam, Kyung Soo Lee, Yoon-La Choi, Myung Jin Chung
Publikováno v:
Clinical Lung Cancer. 20:e309-e316
Purpose To determine the outcomes of transthoracic rebiopsy for epidermal growth factor receptor (EGFR) mutation in patients with lung adenocarcinoma and to explore the clinical and procedure-related risk factors for the acquisition of nondiagnostic
Autor:
Moon Young Choi, Eun Kyung Cho, Hoon Gu Kim, Jinhyun Cho, Hye Ryun Kim, Ha Yeon Lee, Heui June Ahn, Keunchil Park, Ki Hyeong Lee, Myung-Ju Ahn, Hwan Jung Yun, Jin Hyoung Kang, Se-Hoon Lee, Su Jin Lee, K.H. Yoo, Yoonhee Choi, Sin-Ho Jung, Jong Mu Sun, Keon Uk Park, Jin Seok Ahn, Jaeheon Jeong, Kihwan Kim
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose The optimal cytotoxic regimens have not been established for patients with non-small cell lung cancer (NSCLC) who develop disease progression on first-line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Materials and m